[Comparative evaluation using an ergometric test of the efficacy of the 3 major @entity460 antagonists on exertion stable XXXX ].

@entity1 @entity308 @entity1855 @entity3988 @entity951 @entity460 @entity594
@entity594 , @entity3988 and @entity1855 are three effective @entity460 -antagonists in the treatment of @entity951 . We compared their effects on effort @entity951 to evaluate whether one of them is more efficacious. The data were collected from 42 @entity1 (37 males, 5 females; mean age 51 +/- 4) entering one of 3 different trials; the beginning of all trials comprised a two-week, single blind, placebo run-in phase. An exercise stress test was performed at the end of this period and it was considered as basal test for the statistical analysis. Then the 42 @entity1 were divided in 3 groups of 14 and entered a double-blind, randomized phase of drug treatment. The 3 groups started 3 parallel trials: 1) placebo/ @entity594 60 mg/day; 2) placebo/ @entity1855 360 mg/day; 3) placebo/ @entity3988 240 mg/day. The duration of each trial was of 6 weeks (3 weeks of treatment with placebo and 3 weeks with active substance). Exercise stress tests were performed at the end of each phase of the trials, and the resulting data were compared with the data of the test performed at the end of run-in period. Parameters evaluated were: heart rate, blood pressure and rate pressure product at basal conditions, at submaximal and peak exercise; moreover we considered workload, maximal @entity308 , total exercise duration and frequency of exercise-induced @entity951 . @entity1855 reduced rate pressure product at basal condition; all three drugs reduced rate pressure product at submaximal exercise, but a significant statistical difference was found only for @entity1855 and @entity3988 .(ABSTRACT TRUNCATED AT 250 WORDS)
